FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095447519> ?p ?o ?g. }

• W2095447519 endingPage "3397" @default.
• W2095447519 startingPage "3390" @default.
• W2095447519 abstract "In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3Kδ, was evaluated in 54 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) with adverse characteristics including bulky lymphadenopathy (80%), extensive prior therapy (median 5 [range 2-14] prior regimens), treatment-refractory disease (70%), unmutated IGHV (91%), and del17p and/or TP53 mutations (24%). Patients were treated at 6 dose levels of oral idelalisib (range 50-350 mg once or twice daily) and remained on continuous therapy while deriving clinical benefit. Idelalisib-mediated inhibition of PI3Kδ led to abrogation of Akt phosphorylation in patient CLL cells and significantly reduced serum levels of CLL-related chemokines. The most commonly observed grade ≥3 adverse events were pneumonia (20%), neutropenic fever (11%), and diarrhea (6%). Idelalisib treatment resulted in nodal responses in 81% of patients. The overall response rate was 72%, with 39% of patients meeting the criteria for partial response per IWCLL 2008 and 33% meeting the recently updated criteria of PR with treatment-induced lymphocytosis.(1,2) The median progression-free survival for all patients was 15.8 months. This study demonstrates the clinical utility of inhibiting the PI3Kδ pathway with idelalisib. Our findings support the further development of idelalisib in patients with CLL. These trials were registered at clinicaltrials.gov as #NCT00710528 and #NCT01090414." @default.
• W2095447519 created "2016-06-24" @default.
• W2095447519 creator A5000921376 @default.
• W2095447519 creator A5003766253 @default.
• W2095447519 creator A5007254355 @default.
• W2095447519 creator A5011011110 @default.
• W2095447519 creator A5011559739 @default.
• W2095447519 creator A5013974745 @default.
• W2095447519 creator A5015361329 @default.
• W2095447519 creator A5016570475 @default.
• W2095447519 creator A5029401495 @default.
• W2095447519 creator A5037185685 @default.
• W2095447519 creator A5053545098 @default.
• W2095447519 creator A5056235620 @default.
• W2095447519 creator A5060932518 @default.
• W2095447519 creator A5066010864 @default.
• W2095447519 creator A5069054551 @default.
• W2095447519 creator A5071938732 @default.
• W2095447519 creator A5073720570 @default.
• W2095447519 creator A5075675241 @default.
• W2095447519 creator A5088862334 @default.
• W2095447519 date "2014-05-29" @default.
• W2095447519 modified "2023-10-17" @default.
• W2095447519 title "Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia" @default.
• W2095447519 cites W1493876987 @default.
• W2095447519 cites W1719336338 @default.
• W2095447519 cites W1942856476 @default.
• W2095447519 cites W1976402300 @default.
• W2095447519 cites W1983579522 @default.
• W2095447519 cites W1987819921 @default.
• W2095447519 cites W1988340527 @default.
• W2095447519 cites W2006771504 @default.
• W2095447519 cites W2009886463 @default.
• W2095447519 cites W2012228539 @default.
• W2095447519 cites W2012721290 @default.
• W2095447519 cites W2025786205 @default.
• W2095447519 cites W2027971058 @default.
• W2095447519 cites W2038053631 @default.
• W2095447519 cites W2047115666 @default.
• W2095447519 cites W2071549499 @default.
• W2095447519 cites W2072620152 @default.
• W2095447519 cites W2076867321 @default.
• W2095447519 cites W2107561358 @default.
• W2095447519 cites W2112937953 @default.
• W2095447519 cites W2116262245 @default.
• W2095447519 cites W2119900897 @default.
• W2095447519 cites W2124575836 @default.
• W2095447519 cites W2129041705 @default.
• W2095447519 cites W2134645992 @default.
• W2095447519 cites W2136242714 @default.
• W2095447519 cites W2140606816 @default.
• W2095447519 cites W2142099365 @default.
• W2095447519 cites W2143749371 @default.
• W2095447519 cites W2171771895 @default.
• W2095447519 cites W4297674123 @default.
• W2095447519 doi "https://doi.org/10.1182/blood-2013-11-535047" @default.
• W2095447519 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4123414" @default.
• W2095447519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24615777" @default.
• W2095447519 hasPublicationYear "2014" @default.
• W2095447519 type Work @default.
• W2095447519 sameAs 2095447519 @default.
• W2095447519 citedByCount "516" @default.
• W2095447519 countsByYear W20954475192013 @default.
• W2095447519 countsByYear W20954475192014 @default.
• W2095447519 countsByYear W20954475192015 @default.
• W2095447519 countsByYear W20954475192016 @default.
• W2095447519 countsByYear W20954475192017 @default.
• W2095447519 countsByYear W20954475192018 @default.
• W2095447519 countsByYear W20954475192019 @default.
• W2095447519 countsByYear W20954475192020 @default.
• W2095447519 countsByYear W20954475192021 @default.
• W2095447519 countsByYear W20954475192022 @default.
• W2095447519 countsByYear W20954475192023 @default.
• W2095447519 crossrefType "journal-article" @default.
• W2095447519 hasAuthorship W2095447519A5000921376 @default.
• W2095447519 hasAuthorship W2095447519A5003766253 @default.
• W2095447519 hasAuthorship W2095447519A5007254355 @default.
• W2095447519 hasAuthorship W2095447519A5011011110 @default.
• W2095447519 hasAuthorship W2095447519A5011559739 @default.
• W2095447519 hasAuthorship W2095447519A5013974745 @default.
• W2095447519 hasAuthorship W2095447519A5015361329 @default.
• W2095447519 hasAuthorship W2095447519A5016570475 @default.
• W2095447519 hasAuthorship W2095447519A5029401495 @default.
• W2095447519 hasAuthorship W2095447519A5037185685 @default.
• W2095447519 hasAuthorship W2095447519A5053545098 @default.
• W2095447519 hasAuthorship W2095447519A5056235620 @default.
• W2095447519 hasAuthorship W2095447519A5060932518 @default.
• W2095447519 hasAuthorship W2095447519A5066010864 @default.
• W2095447519 hasAuthorship W2095447519A5069054551 @default.
• W2095447519 hasAuthorship W2095447519A5071938732 @default.
• W2095447519 hasAuthorship W2095447519A5073720570 @default.
• W2095447519 hasAuthorship W2095447519A5075675241 @default.
• W2095447519 hasAuthorship W2095447519A5088862334 @default.
• W2095447519 hasBestOaLocation W20954475191 @default.
• W2095447519 hasConcept C126322002 @default.
• W2095447519 hasConcept C197934379 @default.
• W2095447519 hasConcept C203014093 @default.
• W2095447519 hasConcept C2777609679 @default.

• next